IAP Family Proteins and Cancer

描述(申请人提供)：凋亡抑制蛋白(IAP)通常在癌症中过度表达，通过不同的机制抑制细胞凋亡。相反，某些IAPs的内源性抑制物，特别是编码ARTS(Septin4)的基因，似乎作为肿瘤抑制物发挥作用，其表达在某些恶性肿瘤中丢失。IAP家族成员XIAP、c-IAP1和c-IAP2是E3连接酶，催化在涉及赖氨酸48(K48)或K63键的底物上形成多泛素链，其中K48针对蛋白质进行蛋白酶体介导的降解，而K63是与形成信号复合体相关的翻译后修饰。IAP与K48和K63特异的UBC配对的生物学后果是深远的，对于理解癌症的凋亡抵抗机制具有重要意义。例如，c-IAP1和c-IAP2与肿瘤坏死因子受体复合体结合，促进K63连接的RIP1泛素化，这是一种翻译后修饰，抑制RIP1介导的细胞毒性，刺激核因子-β激活，从而帮助细胞存活、细胞增殖和细胞迁移。这项建议阐述了IAP的控制机制及其在肿瘤细胞凋亡抑制和信号转导中的作用。需要检验的中心假设是，控制IAP不同E3连接酶活性的机制在调节这些蛋白质的水平和它们的细胞活动方面发挥着关键作用。具体目标包括：(1)确定IAP的化学拮抗剂(基于模拟Smac)如何刺激其自身定向的K48连接的多泛素化和蛋白酶体依赖的降解；(2)探索IAP与K63-RIP1相互作用对其K63-E3连接酶活性的影响，并验证RIP1结合是K48向K63-特异性连接酶活性转换的关键这一假说；(3)研究c-IAP1和c-IAP2与脱泛素酶CyLD拮抗作用以调节K63泛素化的RIP1的机制，从而调控TnFR1信号复合体的组装，促进或抑制肿瘤坏死因子？诱导的细胞凋亡；(4)探讨XIAP的内源性拮抗剂ARTS的抑瘤作用机制。总之，拟议的研究将揭示IAP作为细胞死亡和信号转导调节因子的多功能本质背后的生化和细胞机制，为癌症治疗的治疗应用提供新的策略。 公共卫生相关性：IAPS是有助于癌细胞存活的抗凋亡蛋白，具有caspase抑制物和信号转导平台的双重功能。这一应用将阐明IAP的E3连接酶活性在驱动信号转导事件和控制细胞生存方面的作用，从而为未来的癌症治疗策略提供见解。

DESCRIPTION (provided by applicant): Inhibitor of Apoptosis Proteins (IAPs) are commonly over-expressed in cancers, suppressing apoptosis through diverse mechanisms. Conversely, certain endogenous inhibitors of IAPs, particularly the gene encoding ARTS (Septin4), appear to operate as tumor suppressors whose expression becomes lost in certain malignancies. IAP family members XIAP, c-IAP1, and c-IAP2 are E3 ligases, catalyzing formation of polyubiquitin chains on substrates involving either lysine 48 (K48) or K63 linkages, where K48 targets proteins for proteasome- mediated degradation while K63 is a post-translational modification associated with formation of signaling complexes. The biological consequences of partnering of IAPs with K48- versus K63-specific UBCs are profound, having important implications for understanding mechanisms of apoptosis resistance of cancers. For example, c-IAP1 and c-IAP2 associate with Tumor Necrosis Factor (TNF) Receptor complexes to promote K63-linked ubiquitinylation of Rip1, a post-translational modification that suppresses Rip1-mediated cytotoxicity and that stimulates NF-?B activation, thereby aiding cell survival, cell proliferation and cell migration. This proposal addresses the mechanisms that control the IAPs and their roles in apoptosis suppression and signal transduction in cancer. The central hypothesis to be tested is that mechanisms controlling the diverse E3 ligase activities of IAPs play a critical role in regulating both the levels of these proteins and their cellular activities. Specific Aims include: (1) Determining how chemical antagonists of IAPs (based on mimicking SMAC) stimulate their self-directed K48-linked polyubiquitination and proteasome-dependent degradation; (2) Exploring the influence of IAP interactions with the kinase Rip1 on their K63-directed E3 ligase activity and testing the hypothesis that Rip1 binding is key to conversion from K48 to K63-specific ligase activity; (3) Addressing the mechanisms by which c-IAP1 and c-IAP2 operate antagonistically with Deubiquitinase CYLD to modulate K63 ubiquitination of Rip1, thereby dictating the assembly of TNFR1 signaling complexes that either promote or suppress TNF?-induced apoptosis; and (4) Investigating the mechanisms by which ARTS, an endogenous antagonist of XIAP, exerts its tumor suppressor effect. Altogether, the proposed studies will reveal the biochemical and cellular mechanisms underlying the multi-functional nature of IAPs as regulators of cell death and signal transduction, suggesting novel strategies for therapeutic applications to cancer treatment. PUBLIC HEALTH RELEVANCE: IAPs are anti-apoptotic proteins that contribute to cancer cell survival, having dual functions as both caspase inhibitors and signal transduction platforms. This application will elucidate the role of the E3 ligase activity of IAPs, in terms of driving signal transduction events and controlling cell survival, thus providing insights for future therapeutic strategies for cancer.